Insider Buying: Fractyl Health (NASDAQ:GUTS) CFO Purchases 20,000 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CFO Weber Lara Smith bought 20,000 shares of the stock in a transaction dated Monday, June 8th. The stock was purchased at an average cost of $0.69 per share, for a total transaction of $13,800.00. Following the acquisition, the chief financial officer owned 20,000 shares of the company’s stock, valued at approximately $13,800. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Fractyl Health Stock Performance

Shares of NASDAQ:GUTS traded down $0.01 during midday trading on Tuesday, hitting $0.66. The stock had a trading volume of 1,197,253 shares, compared to its average volume of 4,031,295. The company has a market capitalization of $105.36 million, a PE ratio of -0.51 and a beta of 2.34. The stock has a 50 day moving average price of $0.67 and a two-hundred day moving average price of $1.08. The company has a current ratio of 4.28, a quick ratio of 4.28 and a debt-to-equity ratio of 1.41. Fractyl Health, Inc. has a 1 year low of $0.38 and a 1 year high of $2.90.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.23. As a group, equities analysts predict that Fractyl Health, Inc. will post -0.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Several large investors have recently made changes to their positions in GUTS. Jane Street Group LLC purchased a new position in shares of Fractyl Health in the second quarter valued at $31,000. FNY Investment Advisers LLC purchased a new position in shares of Fractyl Health in the third quarter valued at $31,000. Jump Financial LLC purchased a new position in shares of Fractyl Health in the fourth quarter valued at $57,000. Scientech Research LLC purchased a new position in shares of Fractyl Health in the third quarter valued at $49,000. Finally, Prelude Capital Management LLC bought a new position in Fractyl Health during the 3rd quarter valued at $55,000.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, June 4th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.